Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures
Cancer is the leading cause of death worldwide. Cancer immunotherapy involves reinvigorating the patient’s own immune system to fight against cancer. While novel approaches like Chimeric Antigen Receptor (CAR) T cells, bispecific T cell engagers, and immune checkpoint inhibitors have shown promising...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1190379/full |
| _version_ | 1797820452129734656 |
|---|---|
| author | Deep Shah Brian Soper Lindsay Shopland |
| author_facet | Deep Shah Brian Soper Lindsay Shopland |
| author_sort | Deep Shah |
| collection | DOAJ |
| description | Cancer is the leading cause of death worldwide. Cancer immunotherapy involves reinvigorating the patient’s own immune system to fight against cancer. While novel approaches like Chimeric Antigen Receptor (CAR) T cells, bispecific T cell engagers, and immune checkpoint inhibitors have shown promising efficacy, Cytokine Release Syndrome (CRS) is a serious adverse effect and remains a major concern. CRS is a phenomenon of immune hyperactivation that results in excessive cytokine secretion, and if left unchecked, it may lead to multi-organ failure and death. Here we review the pathophysiology of CRS, its occurrence and management in the context of cancer immunotherapy, and the screening approaches that can be used to assess CRS and de-risk drug discovery earlier in the clinical setting with more predictive pre-clinical data. Furthermore, the review also sheds light on the potential immunotherapeutic approaches that can be used to overcome CRS associated with T cell activation. |
| first_indexed | 2024-03-13T09:38:34Z |
| format | Article |
| id | doaj.art-9151fa92203443fea21761bcebd7f147 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-13T09:38:34Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-9151fa92203443fea21761bcebd7f1472023-05-25T04:58:11ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-05-011410.3389/fimmu.2023.11903791190379Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futuresDeep Shah0Brian Soper1Lindsay Shopland2In vivo Services, The Jackson Laboratory, Sacramento, CA, United StatesTechnical Information Services, The Jackson Laboratory, Bar Harbor, ME, United StatesIn vivo Services, The Jackson Laboratory, Sacramento, CA, United StatesCancer is the leading cause of death worldwide. Cancer immunotherapy involves reinvigorating the patient’s own immune system to fight against cancer. While novel approaches like Chimeric Antigen Receptor (CAR) T cells, bispecific T cell engagers, and immune checkpoint inhibitors have shown promising efficacy, Cytokine Release Syndrome (CRS) is a serious adverse effect and remains a major concern. CRS is a phenomenon of immune hyperactivation that results in excessive cytokine secretion, and if left unchecked, it may lead to multi-organ failure and death. Here we review the pathophysiology of CRS, its occurrence and management in the context of cancer immunotherapy, and the screening approaches that can be used to assess CRS and de-risk drug discovery earlier in the clinical setting with more predictive pre-clinical data. Furthermore, the review also sheds light on the potential immunotherapeutic approaches that can be used to overcome CRS associated with T cell activation.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1190379/fullcancer immunotherapycytokine release syndromeCAR-T cellsbispecific T cell engagersimmune checkpoint inhibitors |
| spellingShingle | Deep Shah Brian Soper Lindsay Shopland Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures Frontiers in Immunology cancer immunotherapy cytokine release syndrome CAR-T cells bispecific T cell engagers immune checkpoint inhibitors |
| title | Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures |
| title_full | Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures |
| title_fullStr | Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures |
| title_full_unstemmed | Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures |
| title_short | Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures |
| title_sort | cytokine release syndrome and cancer immunotherapies historical challenges and promising futures |
| topic | cancer immunotherapy cytokine release syndrome CAR-T cells bispecific T cell engagers immune checkpoint inhibitors |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1190379/full |
| work_keys_str_mv | AT deepshah cytokinereleasesyndromeandcancerimmunotherapieshistoricalchallengesandpromisingfutures AT briansoper cytokinereleasesyndromeandcancerimmunotherapieshistoricalchallengesandpromisingfutures AT lindsayshopland cytokinereleasesyndromeandcancerimmunotherapieshistoricalchallengesandpromisingfutures |